
1. Eur J Cancer. 2021 Nov;158:253-254. doi: 10.1016/j.ejca.2021.09.007. Epub 2021
Sep 25.

Reply to the letter entitled: Re: The first report on Covid-19 vaccine refusal by
patients with cancer in Italy: Early data from a single-institute survey.

Di Noia V(1), Riva F(2), Di Civita M(2), Cosimati A(2), Cognetti F(3).

Author information: 
(1)Medical Oncology 1 Unit, IRCCS Regina Elena National Cancer Institute, Rome,
Italy. Electronic address: vincenzo.dinoia@gavazzeni.it.
(2)Department of Clinical and Molecular Medicine, Università La Sapienza di Roma,
Italy.
(3)Medical Oncology 1 Unit, IRCCS Regina Elena National Cancer Institute, Rome,
Italy; Department of Clinical and Molecular Medicine, Università La Sapienza di
Roma, Italy.

Comment on
    Eur J Cancer. 2021 Aug;153:260-264.

DOI: 10.1016/j.ejca.2021.09.007 
PMCID: PMC8463326
PMID: 34663560  [Indexed for MEDLINE]

Conflict of interest statement: Conflict of interest statement V.D.N. received
speakers' fee by AstraZeneca, MSD, BMS, Istituto Gentili, Boehringer Ingelheim.
V.D.N. received grant consultancies by Astrazeneca, MSD, BMS, Boehringer
Ingelheim and travels' fee from MSD and Boehringer Ingelheim. V.D.N. received
institutional research grants from Roche. F.C. member of advisory board of GSK,
Roche, Astra Azeneca, Eli-Lilly. FC received speakers’ fee by GSK, Roche,
AstraZeneca, Eli-Lilly, Novartis, Amgen, Pfizer, MSD, BMS, Astellas, Eli-Lilly.
All remaining authors have declared no conflicts of interest.

